{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:25:41Z","timestamp":1793805941869,"version":"4.6.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.06.007","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:19:21Z","timestamp":1784067561000},"page":"369-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Network meta-analysis of immune checkpoint inhibitors in BCG-na\u00efve, high-risk non-muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"44","author":[{"given":"Joseph","family":"McGrath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indraneel","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-2839","authenticated-orcid":false,"given":"K.C.","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.urolonc.2026.06.007_bib0001","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.007_bib0002","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1038\/s41591-025-03738-z","article-title":"Sasanlimab plus Bacillus Calmette\u2013Gu\u00e9rin in BCG-naive, high-risk non\u2013muscle-invasive bladder cancer: the randomized phase 3 CREST trial","volume":"31","author":"Shore","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2026.06.007_bib0003","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(25)01897-5","article-title":"POTOMAC investigators. Durvalumab in combination with Bacillus Calmette\u2013Gu\u00e9rin for BCG-naive, high-risk non\u2013muscle-invasive bladder cancer (POTOMAC): final analysis of a randomized, open-label, phase 3 trial","volume":"406","author":"De Santis","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.007_bib0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.annonc.2025.09.017","volume":"37","author":"Roupr\u00eat","year":"2026","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.06.007_bib0005","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.urolonc.2026.06.007_bib0006","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urolonc.2026.06.007_bib0007","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.007_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003082","article-title":"CINeMA: an approach for assessing confidence in the results of a network meta-analysis","volume":"17","author":"Nikolakopoulou","year":"2020","journal-title":"PLoS Med"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.007_bib0009","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.eururo.2025.12.022","article-title":"Efficacy and safety of checkpoint inhibitors combined with Bacillus Calmette\u2013Gu\u00e9rin in BCG-na\u00efve high-risk non\u2013muscle-invasive bladder cancer: synthesis of evidence from the ALBAN, CREST, and POTOMAC trials","volume":"89","author":"Scilipoti","year":"2026","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.007_bib0010","doi-asserted-by":"crossref","DOI":"10.1200\/OA-25-00151","article-title":"PD-L2 landscape and correlation with outcome: an immunomic analysis","volume":"3","author":"Patwari","year":"2026","journal-title":"JCO Oncol Adv"},{"issue":"9","key":"10.1016\/j.urolonc.2026.06.007_bib0011","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterisation of MEDI4736, an antagonistic anti\u2013PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.007_bib0012","article-title":"Molecular mechanism of PD-1\/PD-L1 blockade via anti\u2013PD-L1 antibodies atezolizumab and durvalumab","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.007_bib0013","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non\u2013muscle-invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"10516","key":"10.1016\/j.urolonc.2026.06.007_bib0014","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0140-6736(25)02015-X","article-title":"Front-line durvalumab and BCG in the treatment of non-muscle-invasive bladder cancer","volume":"406","author":"Necchi","year":"2025","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.007_bib0015","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.euo.2025.06.003","article-title":"The evolving landscape of systemic immunotherapy for Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve high-risk non\u2013muscle-invasive bladder cancer: at the edge of a tsunami?","volume":"8","author":"Gabriel","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.007_bib0016","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/JU.0000000000001515","article-title":"Cost-effectiveness analysis of Pembrolizumab for Bacillus Calmette-Gu\u00e9rin-unresponsive carcinoma In situ of the bladder","volume":"205","author":"Wymer","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.007_bib0017","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bju.16332","article-title":"Cost-effectiveness analysis of different treatment modalities in Bacillus Calmette-Gu\u00e9rin-refractory non-muscle-invasive bladder cancer","volume":"134","author":"Rieger","year":"2024","journal-title":"BJU Int"},{"issue":"10","key":"10.1016\/j.urolonc.2026.06.007_bib0018","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600565X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392600565X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:29:03Z","timestamp":1793802543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392600565X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S107814392600565X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.007","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Network meta-analysis of immune checkpoint inhibitors in BCG-na\u00efve, high-risk non-muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}